Go Pro
→ Elon Musk’s Hushed FCC Filing. Sept 25th. (From Paradigm Press) (Ad)tc pixel Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics logo
$38.10 -0.68 (-1.75%)
Closing price 04:00 PM Eastern
Extended Trading
$38.08 -0.02 (-0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CLDX vs. HALO, ARWR, KRYS, ABVX, and KYMR

Should you buy Celldex Therapeutics stock or one of its competitors? Celldex Therapeutics's main competitors and comparable companies include Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), Krystal Biotech (KRYS), Abivax (ABVX), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 6 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.13 beat Halozyme Therapeutics' score of 0.93 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.70$316.89M$3.3531.94
Celldex Therapeutics$1.54M1,942.85-$258.76M-$4.35N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics24.86% 260.98% 23.91%
Celldex Therapeutics N/A -52.35%-47.61%

Halozyme Therapeutics presently has a consensus price target of $91.20, suggesting a potential downside of 14.77%. Celldex Therapeutics has a consensus price target of $56.42, suggesting a potential upside of 48.08%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Arrowhead Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$829.45M14.05-$1.63M-$2.25N/A
Celldex Therapeutics$1.54M1,942.85-$258.76M-$4.35N/A

Celldex Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Celldex Therapeutics' return on equity of -52.35% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-47.79% -60.06% -17.37%
Celldex Therapeutics N/A -52.35%-47.61%

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals currently has a consensus price target of $99.15, indicating a potential upside of 19.81%. Celldex Therapeutics has a consensus price target of $56.42, indicating a potential upside of 48.08%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.64
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for Arrowhead Pharmaceuticals and 6 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.13 beat Arrowhead Pharmaceuticals' score of 0.95 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Celldex Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Celldex Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech54.82% 19.34% 17.65%
Celldex Therapeutics N/A -52.35%-47.61%

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Krystal Biotech and 6 mentions for Celldex Therapeutics. Krystal Biotech's average media sentiment score of 1.24 beat Celldex Therapeutics' score of 1.13 indicating that Krystal Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M26.28$204.83M$7.9843.30
Celldex Therapeutics$1.54M1,942.85-$258.76M-$4.35N/A

Krystal Biotech presently has a consensus price target of $365.40, indicating a potential upside of 5.74%. Celldex Therapeutics has a consensus price target of $56.42, indicating a potential upside of 48.08%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

Summary

Krystal Biotech beats Celldex Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Celldex Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Celldex Therapeutics' return on equity of -52.35% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -99.02% -70.26%
Celldex Therapeutics N/A -52.35%-47.61%

In the previous week, Celldex Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Celldex Therapeutics and 2 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat Celldex Therapeutics' score of 1.13 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.9% of Abivax shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abivax currently has a consensus price target of $156.38, suggesting a potential upside of 34.87%. Celldex Therapeutics has a consensus price target of $56.42, suggesting a potential upside of 48.08%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

Abivax has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Celldex Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$5.21N/A
Celldex Therapeutics$1.54M1,942.85-$258.76M-$4.35N/A

Summary

Celldex Therapeutics beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Celldex Therapeutics compare to Kymera Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Celldex Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.35% -47.61%
Kymera Therapeutics -285.33%-21.22%-19.21%

In the previous week, Kymera Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for Celldex Therapeutics. Kymera Therapeutics' average media sentiment score of 1.22 beat Celldex Therapeutics' score of 1.13 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Celldex Therapeutics presently has a consensus price target of $56.42, suggesting a potential upside of 48.08%. Kymera Therapeutics has a consensus price target of $130.83, suggesting a potential upside of 11.82%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.88

Celldex Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Celldex Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$1.54M1,942.85-$258.76M-$4.35N/A
Kymera Therapeutics$39.21M248.11-$311.35M-$3.24N/A

Summary

Kymera Therapeutics beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDX vs. The Competition

Export
MetricCelldex TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.05B$3.89B$7.21B$12.81B
Dividend YieldN/A3.63%2.56%10.55%
P/E Ratio-8.7613.60272.8125.11
Price / Sales1,942.851,325.67618.4190.53
Price / CashN/A106.6177.3351.83
Price / Book4.8015.4210.436.18
Net Income-$258.76M-$22.82M$3.49B$358.18M
7 Day Performance-3.23%-3.59%-2.99%-2.34%
1 Month Performance-11.33%0.88%0.02%-2.50%
1 Year Performance52.64%43.89%20.19%9.87%

Celldex Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDX
Celldex Therapeutics
2.1321 of 5 stars		$38.10
-1.8%		$56.42
+48.1%		+59.6%$3.05B$1.54MN/A150
HALO
Halozyme Therapeutics
3.4631 of 5 stars		$107.84
-2.1%		$91.20
-15.4%		+41.2%$12.16B$1.40B31.98390
ARWR
Arrowhead Pharmaceuticals
2.3233 of 5 stars		$85.57
-0.9%		$99.15
+15.9%		+198.0%$11.92B$829.45MN/A400
KRYS
Krystal Biotech
3.5219 of 5 stars		$348.21
-2.8%		$365.40
+4.9%		+146.5%$10.27B$389.13M43.46210
ABVX
Abivax
2.5963 of 5 stars		$115.74
+0.8%		$156.50
+35.2%		+33.8%$9.95BN/AN/A61

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 9/10/2026 by MarketBeat.com Staff.
From Our Partners
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
The secret that called 1929 is flashing something new
In 1929, a young analyst named Irving Weiss studied financial reports while Wall Street partied, then warned o...
Weiss Ratings | Sponsoredtc pixel